The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA’s recent mandate. Hims pushed back against the accusation.
Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs
